[PDF][PDF] Sorafenib induces pyroptosis in macrophages and triggers natural killer cell–mediated cytotoxicity against hepatocellular carcinoma
C Hage, S Hoves, L Strauss, S Bissinger, Y Prinz… - …, 2019 - Wiley Online Library
Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …
[PDF][PDF] Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
MF Sprinzl, F Reisinger, A Puschnik, M Ringelhan… - …, 2013 - Wiley Online Library
Alternatively polarized macrophages (Mϕ) shape the microenvironment of hepatocellular
carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib …
carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib …
Sorafenib relieves cell‐intrinsic and cell‐extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
ML Chen, BS Yan, WC Lu, MH Chen… - … journal of cancer, 2014 - Wiley Online Library
Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
patients with advanced hepatocellular carcinoma (HCC). Cumulating evidence suggests …
[HTML][HTML] Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: Implications from preclinical data for a novel …
Sorafenib, a multikinase inhibitor, is a first-line treatment for advanced hepatocellular
carcinoma, but its long-term effectiveness is limited by the emergence of resistance …
carcinoma, but its long-term effectiveness is limited by the emergence of resistance …
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
M Cao, Y Xu, J Youn, R Cabrera, X Zhang… - Laboratory …, 2011 - nature.com
Accumulating evidence suggests that regulatory T cells (Tregs) and myeloid-derived
suppressor cells (MDSC) are elevated in cancer patients and tumor-bearing hosts, and that …
suppressor cells (MDSC) are elevated in cancer patients and tumor-bearing hosts, and that …
[HTML][HTML] Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma …
Y Yang, M Sun, W Yao, F Wang, X Li… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background There is an urgent need for effective treatments for hepatocellular carcinoma
(HCC). Immunotherapy is promising especially when combined with traditional therapies …
(HCC). Immunotherapy is promising especially when combined with traditional therapies …
[HTML][HTML] TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression
V Ho, TS Lim, J Lee, J Steinberg, R Szmyd, M Tham… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for
advanced HCC, Sorafenib, offers limited survival benefits. Here we assessed whether …
advanced HCC, Sorafenib, offers limited survival benefits. Here we assessed whether …
[PDF][PDF] CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in …
Y Chen, RR Ramjiawan, T Reiberger, MR Ng… - …, 2015 - Wiley Online Library
Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for
advanced hepatocellular carcinoma (HCC) but provides limited survival benefits. Recently …
advanced hepatocellular carcinoma (HCC) but provides limited survival benefits. Recently …
A mesenchymal‐like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells
J Fernando, A Malfettone, EB Cepeda… - … journal of cancer, 2015 - Wiley Online Library
The multikinase inhibitor sorafenib is the only effective drug in advanced cases of
hepatocellular carcinoma (HCC). However, response differs among patients and …
hepatocellular carcinoma (HCC). However, response differs among patients and …
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
KF Chen, HL Chen, WT Tai, WC Feng, CH Hsu… - … of Pharmacology and …, 2011 - ASPET
Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …